Form 4: Ionis Pharmaceuticals Director Michael Hayden Acquires Shares Through RSU Vesting

Ionis Pharmaceuticals Director Michael R. Hayden acquired 4,079 shares of common stock through the vesting of Restricted Stock Units, increasing his direct beneficial ownership to 54,298 shares.

Summary

• Director Michael R. Hayden acquired 4,079 shares of Ionis Pharmaceuticals Inc. common stock on July 15, 2025.
• The acquisition was a result of the vesting and release of a Restricted Stock Unit (RSU) award, with a transaction price of $0.0.
• Following this transaction, Michael R. Hayden directly beneficially owns 54,298 shares of common stock.
• An additional 2,000 shares are indirectly beneficially owned by his spouse through Genworks 2 Consulting, Inc.
• Michael R. Hayden also directly holds 9,897 Restricted Stock Units.
• Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• Restricted Stock Units vest 100% on the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and are delivered on the July 15th following the vesting date.

Sentiment

Score: 7

Explanation: The filing indicates a routine, expected acquisition of shares by a director through RSU vesting, which generally aligns management's interests with shareholders and is a positive signal of continued commitment, though not a direct purchase.

Positives

• Director Michael R. Hayden increased his direct beneficial ownership of Ionis Pharmaceuticals common stock by 4,079 shares.
• The acquisition of shares through RSU vesting aligns the director's interests with those of shareholders.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• 2,000 shares of common stock are indirectly beneficially owned by the reporting person's spouse through Genworks 2 Consulting, Inc., where the spouse has sole voting and investment power.

Stakeholder Impact

• Shareholders may view the director's increased ownership through RSU vesting as a positive sign of alignment between management and shareholder interests.

Next Steps

• Future Restricted Stock Units will vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• Upon vesting, Restricted Stock Units will be delivered to the reporting person on the July 15th following the vesting date.
• Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Director Ownership, Stock Acquisition, Beneficial Ownership, Michael R. Hayden